What is vascular dementia and how should it be managed?

What is Vascular Dementia and Its Management

Vascular dementia (VaD) is cognitive impairment resulting from cerebrovascular disease affecting brain blood vessels—ranging from large vessel strokes to progressive small vessel disease—and should be managed primarily through aggressive vascular risk factor control combined with consideration of cholinesterase inhibitors for symptomatic benefit 1.

Definition and Pathophysiology

VaD represents the second most common cause of dementia after Alzheimer's disease, accounting for approximately 15% of pure dementia cases and an additional 16% when mixed with neurodegenerative pathology 2. The condition encompasses a spectrum from mild vascular cognitive impairment (VCI) to full dementia 3.

The underlying mechanisms include:

• Cerebral hypoperfusion and hypoxia from vascular injury
• Blood-brain barrier disruption and glymphatic dysfunction
• Chronic neuroinflammation and oxidative stress
• White matter demyelination and synaptic failure
• Endothelial dysfunction 4

The vascular injuries range from insidious microvascular changes (white matter hyperintensities, microbleeds, microinfarcts) to single or multiple clinical strokes affecting cognition-critical brain structures 3.

Diagnostic Approach

Use standardized diagnostic criteria and neuroimaging to identify vascular pathology 5. The diagnosis breaks down into four phenotypic categories 6:

• Subcortical ischemic vascular dementia
• Poststroke dementia
• Multi-infarct dementia
• Mixed dementia (vascular + Alzheimer's pathology)

Key diagnostic elements include:

• Neuroimaging showing vascular lesions temporally related to cognitive decline
• Fluid biomarkers: neurofilament light chain, inflammatory markers, and Aβ/tau ratios help identify mixed pathology 4
• Assessment timing matters—up to 60% of stroke survivors develop cognitive impairment in the first year, with 38% having impairment not meeting dementia criteria 3

Management Strategy

Non-Pharmacological Management (Primary Approach)

Aggressive vascular risk factor management forms the cornerstone of both prevention and treatment 1. This is a strong recommendation with moderate quality evidence 1.

Medical risk factors to assess and manage:

• Hypertension (target conventional blood pressure goals; intensive lowering in middle-aged adults with vascular risk factors is weakly recommended) 5
• Diabetes mellitus
• Dyslipidemia
• Atrial fibrillation
• Sleep disorders 1

Lifestyle modifications:

• Diet and sodium intake optimization
• Regular exercise
• Weight management
• Smoking cessation
• Alcohol intake reduction 1

Antithrombotic therapy:

• Use antiplatelet agents (ASA) guided by existing primary/secondary stroke prevention indications 1
• For covert brain infarcts without stroke history: ASA could be considered but benefit is unclear (conditional recommendation) 1
• Follow guideline-based antithrombotic therapy 1

Important caveat: In individuals with significant comorbidities or palliative care goals, discussions about less aggressive or withdrawal of vascular risk reduction may be appropriate 1.

Pharmacological Management

Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine may be considered for vascular or mixed dementia, showing small magnitude benefits in cognitive outcomes 1. This is a conditional recommendation with high quality evidence 1.

Critical points about these medications:

• They are approved by Health Canada/FDA for Alzheimer's disease, not specifically for VCI 1
• Most beneficial when mixed pathology (vascular + Alzheimer's) is present 7
• Provide modest symptomatic improvement rather than disease modification 8, 7
• Physicians should monitor for medications that may worsen cognition 1

Supportive Management

Individuals with VCI require additional support strategies 1:

• Communication tools and memory aids
• Cognitive scaffolding (checklists, structured approaches to tasks)
• Caregiver and family participation in goal-setting
• Task training and environmental modifications
• Referrals to appropriate specialists for comorbidity management (e.g., dysphagia) 1

Education is critical: Patients, families, and caregivers should receive education at multiple points about the expected clinical course and impact on cognition and function 1.

Emerging Therapies

While current FDA-approved options remain limited compared to Alzheimer's disease 8, investigational approaches include:

• Phosphodiesterase inhibitors for cerebral perfusion
• NLRP3 inflammasome inhibitors for neuroinflammation
• Senolytics for cellular senescence
• Remyelination agents for white matter repair 4

However, these remain investigational with limited Phase III data 4.

Common Pitfalls

1. Missing mixed pathology: Many elderly patients have both vascular and Alzheimer's pathology—consider cholinesterase inhibitors more strongly in these cases 1
2. Overlooking driving safety: Approximately 70% of drivers with very mild to mild VCI fail on-road driving tests 1
3. Inadequate secondary prevention: After stroke, cognitive impairment increases dementia risk even if initial impairment is transient 3
4. Underrecognizing functional impact: "Good" functional stroke recovery doesn't guarantee cognitive recovery—patients may be unable to work, drive safely, or manage affairs independently 9

Algorithmic Approach

1. Screen and diagnose using standardized criteria with neuroimaging
2. Aggressively manage all vascular risk factors (strong recommendation)
3. Initiate appropriate antithrombotic therapy based on stroke prevention indications
4. Consider cholinesterase inhibitors if dementia is present, especially with mixed pathology
5. Provide cognitive and environmental support with caregiver involvement
6. Educate continuously about disease trajectory
7. Reassess goals of care as disease progresses or comorbidities accumulate

The evidence strongly supports that prevention through midlife vascular risk management is more effective than treatment once dementia develops 6, 5.